Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758993 | 0.85 | AVPR1A (0.44) | AVPR1AHTTMAPK14GFERMGAM | |
| SCHEMBL4359077 | 0.84 | MGAM (0.53) | AVPR1AHTTMAPK14GFERMGAM | |
| SCHEMBL4359923 | 0.72 | AVPR1A (0.58) | AVPR1AHDAC1HDAC6OXTR | |
| SCHEMBL4356598 | 0.72 | AVPR1A (0.78) | AVPR1AHTTMAPK14GFERMAPT | |
| SCHEMBL2398699 | 0.72 | GPR183 (0.57) | — | |
| SCHEMBL2399002 | 0.72 | HRH4 (0.53) | — | |
| SCHEMBL2398469 | 0.71 | KMT2A (0.57) | HTTGAAMAPTDRD2DRD3 | |
| SCHEMBL2401624 | 0.70 | HRH4 (0.56) | MAPTDRD2DRD3 | |
| SCHEMBL2400179 | 0.70 | HRH4 (0.43) | DRD2DRD3 | |
| SCHEMBL5002805 | 0.70 | HRH3 (0.39) | CRBNDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | claimed |
| EP-1973913-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | AVPR2, OXTR, AVPR1A | AVPR1A 3/4885HTT 700/4885MAPK14 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.